title: Osteosarcoma after bone marrow transplantation.
abstract: Three children treated with bone marrow transplantation for acute lymphoblastic leukemia, Diamond-Blackfan anemia, and congenital amegakaryocytic thrombocytopenia developed secondary osteosarcoma in the left tibia at the age of 13, 13, and 9 years, respectively, at 51, 117, and 106 months after transplantation, respectively. Through treatment with chemotherapy and surgery, all 3 patients are alive without disease. We surveyed the literature and reviewed 10 cases of osteosarcoma after hematopoietic stem cell transplantation (SCT), including our 3 cases. Eight of the patients had received myeloablative total body irradiation before SCT. The mean interval from SCT to the onset of osteosarcoma was 6 years and 4 months, and the mean age at the onset of osteosarcoma was 14 years and 5 months. The primary site of the post-SCT osteosarcoma was the tibia in 6 of 10 cases, in contrast to de novo osteosarcoma, in which the most common site is the femur. At least 7 of the 10 patients are alive without disease. Osteosarcoma should be one of the items for surveillance in the follow-up of patients who undergo SCT.
authors.affiliation: Department of Pediatrics, Nagoya Medical Center, National Hospital Organization, Narita City, Japan. uekih@naritasekijyuji.jp
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ueki
authors.forename: Naoko
authors.initials: N
authors.lastname: Maeda
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sekimizu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tsukushi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nishida
authors.forename: Keizo
authors.initials: K
authors.lastname: Horibe
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000209:etiology*; D002648:Child; D006801:Humans; D008297:Male; D012516:Osteosarcoma / Q000209:etiology*